Advanced

AJNR - American Journal of Neuroradiology

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gaviani, P. Articles by Henson, J.W. Search for Related Content PubMed PubMed Citation Articles by Gaviani, P. Articles by Henson, J.W.

American Journal of Neuroradiology 27:605-608, March 2006
© 2006 American Society of Neuroradiology

BRAIN

Improved Detection of Metastatic Melanoma by T2*-Weighted Imaging

P. Gaviani^a, M.E. Mullins^b,e, T.A. Braga^a, E.T. Hedley-Whyte^c,e, E.F. Halpern^d,e, P.S. Schaefer^b,e and J.W. Henson^a,b,e

^a Stephen E. and Catherine Pappas Center for Neuro-Oncology, Harvard Medical School, Boston, Mass
^b Division of Neuroradiology, Harvard Medical School, Boston, Mass
^c Division of Neuropathology, Harvard Medical School, Boston, Mass
^d Department of Radiology, Harvard Medical School, Boston, Mass
^e Massachusetts General Hospital, Harvard Medical School, Boston, Mass

Address correspondence to John W. Henson, MD, Division of Neuroradiology and Stephen E. and Catherine Pappas Center for Neuro-Oncology Center, Massachusetts General Hospital, Yawkey 9E, Fruit St, Boston, MA 02114

BACKGROUND AND PURPOSE: The imaging features of metastatic melanomas are distinctive due to the presence of melanin and the propensity for hemorrhage. Both hemorrhage and melanin can produce T1-weighted hyperintensity and T2*-weighted signal intensity loss. We hypothesized that T2*-weighted images would improve detection of metastatic melanoma.

METHODS: The T2* and T1 characteristics of 120 newly detected metastatic brain lesions from 31 patients with malignant melanoma were compared with those of 120 brain metastases from 23 patients with lung cancer.

RESULTS: Melanoma metastases were 5 times more likely to demonstrate prominent T2*-related signal intensity loss (susceptibility effect) than were lung metastases (42% vs 8%; P < .01), and 4.5 times more likely to demonstrate T1 hyperintensity (55% vs 12%; P < .01). Patients with melanoma had lesions that were either hypointense on T2*-weighted images, hyperintense on T1 images, or both, in 71% (85/120), compared with 19% (23/120) of lung carcinoma metastases (P < .01). Melanoma lesions were 16 times more likely than lung cancer lesions to show combined T2* related signal intensity loss and T1 hyperintensity (P < .01). Remarkably, 8 melanoma lesions (7%) in 3 patients were detectable principally on the T2*-weighted sequences, whereas no lung cancer lesion was detected solely on susceptibility images. We found a direct correlation between melanin content and T1 hyperintensity but no correlation between T2* intensity and melanin.

CONCLUSION: T2*-weighted images improve lesion detection in patients with melanoma metastases, and in conjunction with T1-weighted sequences, can suggest melanoma as the etiology of an intracranial mass. This sequence should be employed for evaluation of possible brain metastasis in patients without a known primary malignancy and in studies for melanoma staging.

This article has been cited by other articles:

				A. Jayashankar, S. M. Sabourin, and M. E. Mullins Imaging of Metastatic Malignant Melanoma to the Head: Self-Assessment Module Am. J. Roentgenol., September 1, 2008; 191(3_Supplement): S22 - S24. [Abstract] [Full Text] [PDF]